InDex Pharmaceuticals Holding AB (publ) announced that the Board of Directors has named Jenny Sundqvist as new CEO. Jenny comes from a position as Chief Commercial Officer at Isofol Medical AB and has broad experience from leading positions within the pharmaceutical industry. Johan Giléus, who has been acting CEO since April 2022, will continue as CFO in the company.

Jenny Sundqvist has an impressive track record of developing companies and creating value. She has broad experience in leading successful research organizations in combination with commercial experience in marketing of approved medications. Jenny has previously, among other things, worked as Chief Commercial Officer at Isofol Medical AB, been responsible for AstraZeneca's global research portfolio in oncology, worked as Site Director for AstraZeneca's research unit in Gothenburg and been global brand manager for AstraZeneca's asthma product Symbicort.

Jenny will take over as CEO from January 1, 2023.